Welcome to our dedicated page for NeOnc Technologies Holdings news (Ticker: NTHI), a resource for investors and traders seeking the latest updates and insights on NeOnc Technologies Holdings stock.
NeOnc Technologies Holdings, Inc. (NTHI) is a clinical-stage biotechnology leader focused on central nervous system therapeutics and advanced drug delivery systems. This page provides investors and industry observers with timely updates on clinical trial progress, regulatory developments, and strategic initiatives critical to evaluating the company's position in the CNS treatment market.
Access consolidated information on NTHI's proprietary NEO platform advancements, intellectual property milestones, and collaborative research partnerships. The resource covers essential updates including FDA designations, trial phase results, and executive commentary without speculative analysis.
Key content types include earnings communications, clinical trial status reports, patent filings, and leadership updates. All materials maintain compliance with financial disclosure regulations while emphasizing technological developments in blood-brain barrier penetration techniques.
Bookmark this page for streamlined tracking of NTHI's progress in addressing complex neurological conditions through its innovative therapeutic pipeline. Regular updates ensure stakeholders remain informed about developments that may influence long-term research trajectories and market positioning.
NeOnc Technologies (NTHI), a clinical-stage biopharmaceutical company focused on CNS cancer therapies, has appointed Dr. David M. Ashley to its Scientific Advisory Board. Dr. Ashley serves as the Director of The Preston Robert Tisch Brain Tumor Center at Duke University and holds the position of Rory David Deutsch Distinguished Professor of Neuro-Oncology.
Dr. Ashley brings significant expertise in brain tumor immunology and epigenetics, with experience in both pediatric and adult brain cancers. His appointment is expected to strengthen NeOnc's pipeline, particularly the development of lead candidates NEO100™ and NEO212™. Since 2018, he has led one of North America's largest dedicated brain tumor centers, integrating clinical care, translational research, and education.
NeOnc Technologies (NTHI), a clinical-stage biopharmaceutical company focused on central nervous system (CNS) cancers, has appointed Dr. Alexandra M. Miller to its Scientific Advisory Board. Dr. Miller serves as Chief of Neuro-Oncology and Co-Director of the Brain and Spine Tumor Center at NYU Langone Health's Perlmutter Cancer Center.
Dr. Miller's expertise in liquid biopsy assays for CNS tumors and cerebrospinal fluid diagnostics will support NeOnc's clinical trials for NEO100™ and NEO212™. The appointment coincides with NeOnc's expansion of its global trial network into the Middle East and India, strengthening the company's position in brain cancer research.
NeOnc Technologies (NTHI), a clinical-stage biopharmaceutical company focused on CNS cancer therapies, has appointed Dr. Henry S. Friedman to its scientific advisory board. Dr. Friedman, a distinguished neuro-oncologist from Duke University's Preston Robert Tisch Brain Tumor Center, brings extensive expertise with over 500 peer-reviewed publications.
As a deputy director at the Brain Tumor Center and holder of the James B. Powell, Jr. Distinguished Professorship, Dr. Friedman's appointment comes at a crucial time as NeOnc prepares to publish data from its NEO100™ and NEO212™ clinical programs. His expertise will be instrumental in reviewing and validating these upcoming results, particularly in the areas of glioblastoma and other brain cancers.
NeOnc Technologies (NASDAQ:NTHI), a clinical-stage biotech company, will be featured on "Health Uncensored with Dr. Drew" on the Lifetime Network, reaching approximately 63 million TV households on September 25th at 8:00 a.m. ET/PT.
The company has achieved several key milestones, including a $50 million strategic partnership with Quazar Investment, FDA authorization for Phase II trials of NEO212, and $2.5 million in NIH grants. NeOnc's NEO™ platform technology focuses on delivering therapies across the Blood-Brain Barrier to treat brain cancer, with two drug candidates (NEO100™ and NEO212™) currently in clinical trials under FDA Fast-Track status.
NeOnc Technologies (NASDAQ: NTHI) has received FDA authorization to proceed with Phase IIa/IIb clinical trial of NEO212, its first-in-class oral chemical conjugated chemotherapy for brain cancer. The approval follows successful Phase I completion, which demonstrated safe administration at doses up to 810 mg daily on Days 1-5 of a 28-day cycle.
NEO212 combines Temozolomide (TMZ), the current standard treatment for glioblastoma, with NEO100, NeOnc's proprietary form of perillyl alcohol. The drug aims to overcome TMZ's limitations by enhancing blood-brain barrier penetration and antitumor activity. Patient enrollment is expected to begin by end of 2025, expanding from 4 current trial sites to multiple premier cancer institutions across the U.S.
NeOnc Technologies (NASDAQ:NTHI) has completed the acquisition of a strategic intellectual property portfolio focused on AI, 3D bioprinting, and quantum modeling technologies for $3.5 million ($500,000 cash and $3 million in stock at $25/share). The acquired technology, including U.S. Patent No. 11,788,057 B2, enables the creation of sophisticated patient-derived 3D brain tumor models.
The acquisition enhances NeOnc's drug discovery capabilities by combining AI and quantum modeling algorithms with realistic biological environments for more efficient therapeutic candidate screening. Alongside this development, the company appointed Dr. Ishwar K. Puri, Senior Vice President of Research and Innovation at USC and a globally recognized scholar, to its Board of Directors.
NeOnc Technologies (NASDAQ: NTHI), a clinical-stage biotech company focused on CNS cancer therapies, reported Q2 2025 results and significant operational developments. The company secured a $50 million strategic partnership with Quazar Investment and received a $2.5 million NIH grant. Key financial metrics show increased expenses with G&A at $984K (up from $290K) and R&D at $677K (up from $394K), resulting in a net loss of $5.68M.
Clinical progress includes advancing multiple trials: NEO100-01 for malignant gliomas (Phase 2a enrollment expected by September 2025), NEO212 for brain cancer (final Phase I cohort completion in 2025), and NEO100-3 for pediatric indications. The company also acquired an AI and quantum modeling IP portfolio and joined the Russell Microcap® Index.
NeOnc Technologies (NASDAQ: NTHI), a multi-Phase 2 clinical-stage biotech company, has completed all contingencies for a $50 million strategic partnership with Quazar Investment following the incorporation of NuroMENA Holdings Ltd. by the Abu Dhabi Global Market (ADGM).
The partnership involves Quazar Investment taking majority control of NuroMENA Holdings, which will serve as NeOnc's UAE-based subsidiary overseeing regional clinical operations in the Middle East and North Africa. The collaboration aims to accelerate the development of NeOnc's CNS therapeutic pipeline, including the NEO212 and NEO100 clinical programs for brain cancer treatment.
Quazar Investment, managing over $3.3 billion in assets, will provide strategic support to expand NeOnc's CNS platform across the MENA region, with joint governance oversight between both companies.
NeOnc Technologies (NASDAQ: NTHI) has secured $2.5 million in NIH STTR grants to advance its proprietary compound NEO212. The funding includes a $400,000 Phase 1 grant for acute myelogenous leukemia (AML) studies and a $2.1 million Phase 2 grant for newly diagnosed gliomas research.
The company is currently completing Phase 1 clinical trials for NEO212, with these non-dilutive funds supporting its expansion into new indications. The grants are structured as collaborative developments between NeOnc (40% funding) and USC-based research collaborators (60% funding), led by Dr. Thomas Chen as Principal Investigator.
NeOnc Technologies (NASDAQ: NTHI), a clinical-stage biotech company focused on brain and central nervous system cancer treatments, was featured on Yahoo Finance's Trader Talk podcast. The episode highlights the company's recent achievements, including its successful IPO, a $50 million partnership in the Middle East, and inclusion in the Russell Microcap Index.
The podcast discussion with Executive Chairman Amir Heshmatpour covers NeOnc's innovative intranasal drug delivery approach for brain cancer, its strategic partnership with USC's medical school, and the expansion of global clinical trials. The conversation also explores the potential impact of AI and quantum computing in biotechnology.
FAQ
What is the current stock price of NeOnc Technologies Holdings (NTHI)?
What is the market cap of NeOnc Technologies Holdings (NTHI)?
